Subjective Cognitive Decline
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Community-dwelling adults aged 70 years or older Individuals who are able to walk independently or are independent in mobility Individuals who can understand the study and provide informed consent
Exclusion criteria
Exclusion criteria: Individuals who meet the contraindications or exclusion criteria for Mirevo, including those with severe ophthalmologic diseases that prevent eye tracking or visual recognition of the projected screen. Specifically: Individuals with blindness, low vision, glaucoma, retinitis pigmentosa, diabetic retinopathy, age-related macular degeneration, visual field defects, central scotoma, visual field loss, color vision disorders, or light perception disorders. Individuals with active neurological or psychiatric diseases, including multiple sclerosis, amyotrophic lateral sclerosis, Guillain-Barre syndrome, encephalitis or meningitis, schizophrenia, severe depression, bipolar disorder, or severe personality disorders. Individuals diagnosed with Alzheimer's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, or mild cognitive impairment (MCI) by a medical institution.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total score of the Japanese version of the Frenchay Activities Index(SR-FAI),assessed once at baseline. | — |
Secondary
| Measure | Time frame |
|---|---|
| Score of the self-administered dementia checklist (used to assess/classify SCD) Subscale scores of the Japanese SR-FAI Mirevo score (objective cognitive function assessment) GDS-15 score (depressive symptoms) Demographics (age, sex, years of education, etc.) | — |
Countries
Japan
Contacts
Graduate School of Health Sciences, Kobe University Department of Rehabilitation Sciences